doi:10.3969/j.issn.1004-583X.2023.05.018

Abstract

CLC Number:

R581.1

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2023.05.018

https://huicui.hebmu.edu.cn/EN/Y2023/V38/I5/477

References 18

[1]	De Leo S, Lee SY, Braverman LE. Hyperthyroidism[J]. Lancet, 2016, 388(10047):906-918. doi: 10.1016/S0140-6736(16)00278-6 pmid: 27038492
[2]	Leger J, Carel JC. Diagnosis and management of hyperthyroidism from prenatal life to adolescence[J]. Best Pract Res Clin Endocrinol Metab, 2018, 32(4):373-386. doi: S1521-690X(18)30062-9 pmid: 30086864
[3]	Mooij CF, Cheetham TD, Verburg FA, et al. 2022 European thyroid association guideline for the management of pediatric Graves' disease[J]. Eur Thyroid J, 2022, 11(1):e210073.
[4]	Sawicka B, Borysewicz-Sanczyk H, Wawrusiewicz-Kurylonek N, et al. Analysis of polymorphisms rs7093069-IL-2Ra, rs7138803-FAIM2, and rs1748033-PADI4 in the group of adolescents with autoimmune thyroid diseases[J]. Front Endocrinol(Lausanne), 2020, 11(10):544658.
[5]	Lane LC, Kus A, Bednarczuk T, et al. An intronic HCP5 variant is associated with age of onset and susceptibility to Graves disease in UK and Polish cohorts[J]. J Clin Endocrinol Metab, 2020, 105(9):e3277-3284. doi: 10.1210/clinem/dgaa347 URL
[6]	Davies TF, Andersen S, Latif R, et al. Graves’ disease[J]. Nat Rev Dis Primers, 2020, 6(1):53. doi: 10.1038/s41572-020-0195-8
[7]	De Luca F, Valenzise M. Controversies in the pharmacological treatment of Graves' disease in children[J]. Expert Rev Clin Pharmacol, 2018, 11(11):1113-1121. doi: 10.1080/17512433.2018.1546576 URL
[8]	Wood CL, Cole M, Donaldson M, et al. Randomised trial of block and replace vs dose titration thionamide in young people with thyrotoxicosis[J]. Eur J Endocrinol, 2020, 183(6):637-645. doi: 10.1530/EJE-20-0617 pmid: 33107439
[9]	Ohye H, Minagawa A, Noh JY, et al. Antithyroid drug treatment for Graves’ disease in children: A long-term retrospective study at a single institution[J]. Thyroid, 2014, 24(2):200-207. doi: 10.1089/thy.2012.0612 URL
[10]	López-Valverde L, Domènech È, Roguera M, et al. Spontaneous reporting of adverse drug reactions in a pediatric population in a tertiary hospital[J]. J Clin Med, 2021, 10(23):5531. doi: 10.3390/jcm10235531 URL
[11]	Azizi F, Takyar M, Madreseh E, et al. Long-term methimazole therapy in juvenile Graves’ disease: A randomized trial[J]. Pediatrics, 2019, 143(5):e20183034.
[12]	van Lieshout JM, Mooij CF, et al. Methimazole-induced remission rates in pediatric Graves’disease: A systematic review[J]. Eur J Endocrinol, 2021, 185(2):219-229. doi: 10.1530/EJE-21-0077 pmid: 34061770
[13]	Léger J, Oliver I, Rodrigue D, et al. Graves' disease in children[J]. Ann Endocrinol (Paris), 2018, 79(6):647-655. doi: S0003-4266(18)31214-9 pmid: 30180972
[14]	Silberstein EB, Alavi A, Balon HR, et al. The SNMMI practice guideline for therapy of thyroid disease with I-131 3.0[J]. J Nucl Med, 2012, 53(10):1633-1651. doi: 10.2967/jnumed.112.105148 URL
[15]	Lutterman SL, Zwaveling-Soonawala N, Verberne HJ, et al. The efficacy and short- and long-term side effects of radioactive iodine treatment in pediatric Graves’ disease: A systematic review[J]. Eur Thyroid J, 2021, 10(5):353-363. doi: 10.1159/000517174 pmid: 34540705
[16]	Annerbo M, Stalberg P, Hellman P. Management of Grave’s disease is improved by total thyroidectomy[J]. World J Surg, 2012, 36(8):1943-1946. doi: 10.1007/s00268-012-1617-x pmid: 22547016
[17]	Rivkees SA. Pediatric Graves’ disease: Management in the postpropylthiouracil era[J]. Int J Pediatr Endocrinol, 2014, 2014(1):10. doi: 10.1186/1687-9856-2014-10 pmid: 25089127
[18]	Zaat AS, Derikx JPM, Zwaveling-Soonawala N, et al. Thyroidectomy in pediatric patients with Graves’ disease:A systematic review of postoperative morbidity[J]. Eur Thyroid J, 2021, 10(1):39-51.

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 18

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Feng Jue. Correct diagnosis and standardized treatment of Graves' hyperthyroidism [J]. Clinical Focus, 2016, 31(3): 233-236.
[2]	Zhang Lihui, Yuan Lingling. Progress in diagnosis and treatment of subclinical hyperthyroidism [J]. Clinical Focus, 2016, 31(3): 237-240.
[3]	Lu Xiaowei, Zhou Hong. Diagnosis and treatment in Graves’ ophthalmopathy [J]. Clinical Focus, 2016, 31(3): 241-245.
[4]	Zhang Rongjin,Hao Yongmei. Pathogenesis and treatment of patients with Graves disease presenting with leucopenia or agranulocytosis [J]. Clinical Focus, 2016, 31(3): 246-249.
[5]	Li Hui,Li Jing. Recent progress in treatment of anti-thyroid drugs on pregnant women with hyperthyroidism [J]. Clinical Focus, 2016, 31(3): 254-257.
[6]	Liu Zhihong,Wang Ruiying. Influence of pregnancy hyperthyroidism on offspring brain development [J]. Clinical Focus, 2016, 31(3): 258-261.
[7]	Wang Yong;Ding Yong;Xing Jialiu;Zhang Youren;Guan Meichao. Bone mineral density change in hyperthyroidism patients before and after 131 I treatment [J]. Clinical Focus, 2015, 30(1): 74-77.
[8]	. @@ [J]. Clinical Focus, 2014, 29(10): 1198-1200.
[9]	HE Ke;HU Yun;GUO Mu-hong;MAO Xiao-ming. Thyrotropin receptor antibody induced-apoptosis and proliferation in human hepatoma HepG2 cells [J]. Clinical Focus, 2014, 29(1): 45-48.
[10]	. [J]. CLINICAL FOCUS, 2013, 28(12): 1411-1412.
[11]	. [J]. CLINICAL FOCUS, 2013, 28(10): 1141-1142.
[12]	. [J]. CLINICAL FOCUS, 2013, 28(10): 1143-1144.
[13]	WANG Yan-fang;DING Chang-xia;LIU Cun-jie;ZHAO Hai-yun;LI Chong;ZHANG Xiu-li;HAN Hong-wei. Intracranial atherosclerotic changes ofdoi:ents with hyperthyroidism by transcranial Doppler ultrasound and carotid ultrasonography [J]. CLINICAL FOCUS, 2013, 28(8): 844-847.
[14]	DING Chang-xia;WANG Yan-fang;LIU Cun-jie;ZHAO Hai-yun;LI Chong;ZHANG Xiu-li;HAN Hong-wei. Clinical research on intracranial arteriostenosis in patients with hyperthyroidism in high iodine area of Huanghua [J]. Clinical Focus, 2013, 28(4): 403-405408.
[15]	. [J]. CLINICAL FOCUS, 2013, 28(3): 306-307.